Precision BioSciences, Inc.
DTIL · NASDAQ
Market closed$7.87$-0.450000 (-5.41%)After hours $7.82 · -0.59%
Key statistics
Previous close$8.32
Open$8.05
Day high$8.35
Day low$7.85
52-week high$9.62
52-week low$3.53
Market cap100.96M
Volume287.00K
Average volume412.64K
P/E ratio-1.99
Forward P/E—
EPS-3.95
Dividend yield0.00%
Market context
Why it moved
DTIL (Precision BioSciences) declined sharply amid elevated implied volatility in its options market and broad selling pressure, with no specific positive catalysts to support the stock as it drifted lower from its previous close.
What is happening
Recent company-specific developments and publisher coverage.
Moomoo · July 9, 2026H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60Stock Titan · July 1, 2026Precision BioSciences (NASDAQ: DTIL) shares HBV data, DMD trial timelinePrecision BioSciences · May 27, 2026Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026Investing.com · May 27, 2026Precision BioSciences stock jumps on hepatitis B trial dataBioSpace · May 22, 2026Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026Stock Titan · May 21, 2026Gene editing for hepatitis B: Precision BioSciences to share new dataBusiness Wire · May 5, 2026Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business UpdateEuropean AIDS Treatment Group · April 15, 2026Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences Benzinga · July 1, 2026Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Trial Evaluating PBGENE-DMD For Duchenne Muscular Dystrophy; Initial Safety Data Targeted For End-2026 Mt Newswire · June 29, 2026Precision BioSciences Joins Russell 2000 Index Mt Newswire · June 9, 2026Oppenheimer Initiates Precision BioSciences at Outperform Benzinga · May 27, 2026Why Is Precision BioSciences Stock Gaining Wednesday? Benzinga · May 27, 2026Precision BioSciences Reports PBGENE-HBV Achieves 100% pgRNA Loss And 10-Fold cccDNA Transcript Reduction In ELIMINATE-B Study Benzinga · May 21, 2026Precision BioSciences Announces Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Benzinga · May 14, 2026Precision BioSciences Announces New Preclinical Data From PBGENE-DMD Program In Oral Presentation At ASGCT 2026 Annual Meeting Benzinga · April 29, 2026Precision Biosciences Starts Phase 1/2 FUNCTION-DMD Study Of PBGENE-DMD, In Vivo Gene Editing Treatment For Duchenne Muscular Dystrophy